PL1945272T3 - Sposób prowadzenia scyntygraffi - Google Patents

Sposób prowadzenia scyntygraffi

Info

Publication number
PL1945272T3
PL1945272T3 PL06819185T PL06819185T PL1945272T3 PL 1945272 T3 PL1945272 T3 PL 1945272T3 PL 06819185 T PL06819185 T PL 06819185T PL 06819185 T PL06819185 T PL 06819185T PL 1945272 T3 PL1945272 T3 PL 1945272T3
Authority
PL
Poland
Prior art keywords
scintigraphy
Prior art date
Application number
PL06819185T
Other languages
English (en)
Inventor
Hanspeter Nick
Rene Lattmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0522302A external-priority patent/GB0522302D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1945272T3 publication Critical patent/PL1945272T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL06819185T 2005-11-01 2006-10-30 Sposób prowadzenia scyntygraffi PL1945272T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0522302A GB0522302D0 (en) 2005-11-01 2005-11-01 Organic compound
US74678406P 2006-05-09 2006-05-09
PCT/EP2006/067916 WO2007051773A1 (en) 2005-11-01 2006-10-30 Method of scintigraphy
EP06819185.7A EP1945272B1 (en) 2005-11-01 2006-10-30 Method of scintigraphy

Publications (1)

Publication Number Publication Date
PL1945272T3 true PL1945272T3 (pl) 2014-03-31

Family

ID=37714608

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06819185T PL1945272T3 (pl) 2005-11-01 2006-10-30 Sposób prowadzenia scyntygraffi

Country Status (5)

Country Link
US (1) US7947673B2 (pl)
EP (1) EP1945272B1 (pl)
JP (1) JP5322651B2 (pl)
PL (1) PL1945272T3 (pl)
WO (1) WO2007051773A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
EP2416788A4 (en) * 2009-04-07 2012-08-22 Lawrence Bernstein IDENTIFICATION AND TREATMENT OF CANCER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618838A (en) 1993-06-18 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Gallium complexes for the treatment of free radical-induced diseases
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
AU744179B2 (en) 1998-04-08 2002-02-14 Oregon Health Sciences University Enhancement of cellular gallium uptake
US6602989B1 (en) 2000-05-17 2003-08-05 The Research Foundation Of State University Of New York Synthesis, characterization, and application of pyridylazo bioconjugates as diagnostic and therapeutic agents
GB0126618D0 (en) 2001-11-06 2002-01-02 Novartis Ag Organic compounds
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1945272B1 (en) 2013-09-11
US7947673B2 (en) 2011-05-24
JP5322651B2 (ja) 2013-10-23
JP2009513688A (ja) 2009-04-02
EP1945272A1 (en) 2008-07-23
US20080279962A1 (en) 2008-11-13
WO2007051773A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
GB0823478D0 (en) Method of cementing
IL207493A0 (en) Method of securing pipe elements together
EP1864785A4 (en) SETEROLITHOGRAPHIEVERFAHREN
IL185757A0 (en) Methods of decreasing calcifcation
ZA200802598B (en) Chemo-immunotherapy method
GB0520375D0 (en) Method
GB0509433D0 (en) Method
GB0520235D0 (en) Method
GB0524190D0 (en) Method
EP1964538A4 (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
GB0502046D0 (en) Method
GB0523366D0 (en) Method
GB0508420D0 (en) Method
GB0515695D0 (en) Method
GB0505756D0 (en) Method
PL1945272T3 (pl) Sposób prowadzenia scyntygraffi
GB0522193D0 (en) Method
GB0520981D0 (en) Method
GB0518667D0 (en) Method
GB0525446D0 (en) Method
PT1945272E (pt) Método de cintigrafia
GB0522201D0 (en) Method
GB0504182D0 (en) Method
GB0523250D0 (en) Method